ArticleFrontiers in public health2026
Cost-effectiveness of first-line aumolertinib versus osimertinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer in China.
Yuhua Wu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.